August 2004
Worldwide Biotech;Aug2004, Vol. 16 Issue 8, p6
Trade Publication
Reports on the agreement between Vertex Pharmaceuticals Inc. and Mitsubishi Pharma Corp. to develop and commercialize VX-950, Vertex's investigational oral protease inhibitor for the treatment of hepatitis C virus. Payments to be given by Mitsubishi to Vertex as part of the agreement; Statement from Joshua Boger, Vertex chairman and CEO, on the partnership; Capabilities of VX-950.


Related Articles

  • Telaprevir.  // Drugs in R&D;2010, Vol. 10 Issue 3, p179 

    Telaprevir (LY 570310; LY-570310; LY570310;MP 424;MP-424; VX 950; VX-950) is an orally administered peptidomimetic inhibitor of the hepatitis C virus (HCV) protease NS3/4A. It is being developed by Vertex Pharmaceuticals and its licensees for the treatment of HCV infections and has recently been...

  • Telaprevir Looks Ever-Better, But Don't Discount Boceprevir. Morrison, Trista // BioWorld Insight;8/16/2010, Vol. 18 Issue 33, p3 

    The article reports on the competition in the development of effective pharmacology for hepatitis C virus (HCV). Accordingly, Vertex Pharmaceuticals Inc. has reported a 75 percent HCV cure rate from the protease inhibitor telaprevir, while the boceprevir from Merck & Co. Inc. has reported a 66...

  • Nearing Telaprevir Endgame, Vertex Bulks up War Chest. Boggs, Jennifer // BioWorld Today;7/31/2009, Vol. 20 Issue 146, p1 

    The article reports on the additional investments achieved by Vertex Pharmaceuticals Inc. in relation to the final development stage of its hepatitis C drug telaprevir as of July 31, 2009. As stated, the company received $160 million in exchange for royalty rights for two protease inhibitors...

  • Telaprevir Data Head to Expanded HCV Market.  // Bioworld Week;8/16/2010, Vol. 18 Issue 33, p4 

    The article reports on the second Phase III trial conducted by the Cambridge, Massachusetts-based Vertex Pharmaceuticals Inc. to its hepatitis C virus (HCV) protease inhibitor called telaprevir, which showed 72% cure rate for the disease.

  • INCIVEK.  // MPR - Residents' Edition;Fall/Winter2011, Vol. 20 Issue 2, pA:6 

    The article offers brief clinical and pharmacological information on Incivek, a hepatitis C virus protease inhibitor with telaprevir for treatment of chronic hepatitis C genotype 1 infection from Vertex Pharmaceuticals Inc.

  • Telaprevir Data Illuminate Path to Expanded HCV Market. Morrison, Trista // BioWorld Today;8/11/2010, Vol. 21 Issue 154, p1 

    The article offers information on the 75 and 72 percent cure rate in the first and second Phase III trials of hepatitis C virus (HCV) protease inhibitor telaprevir from Vertex Pharmaceuticals Inc. It suggests that these findings may help telaprevir in penetrating expanded HCV market consisting...

  • Telaprevir's Response-Guided rial Helps HCV Get Personal. Morrison, Trista // BioWorld Insight;5/31/2010, Vol. 18 Issue 22, p3 

    The article focuses on the concept of Vertex Pharmaceuticals Inc. and Merck & Co. Inc. on using early viral load measurements in the Phase III trials of their Hepatitis C virus (HCV) protease inhibitors, telaprevir and boceprevir. It says that protease inhibitors allowed patients to achieve an...

  • EASL Roundup.  // BioWorld Today;4/28/2009, Vol. 20 Issue 80, p7 

    The article offers a look at additional data presented by the Vertex Pharmaceuticals Inc. from its phase IIb clinical trial of protease inhibitor telaprevir in treatment-experienced hepatitis C virus patients. The final data from Phase IIb trial were similar to previously presented interim data....

  • Vertex Pharmaceuticals to acquire ViroChem Pharma.  // PharmaWatch: Biotechnology;Apr2009, Vol. 8 Issue 4, p22 

    The article reports on the announcement by Vertex Pharmaceuticals Inc. that it will acquire ViroChem Pharma. The acquisition of ViroChem Pharma will allow Vertex Pharmaceuticals Inc., a biotechnology company, to add two polymerase inhibitors to its hepatitis C virus drug development. Under a...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics